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Abstract
Introduction or background: The UK is at the forefront of mitochondrial
science and is currently the only country in the world to legalize germ-line
technologies involving mitochondrial donation. However, concerns have
been raised about genetic modiﬁcation and the ‘slippery slope’ to designer
babies.
Sources of data: This review uses academic articles, newspaper reports and
public documents.
Areas of agreement: Mitochondrial donation offers women with mitochon-
drial disease an opportunity to have healthy, genetically related children.
Areas of controversy: Key areas of disagreement include safety, the creation
of three-parent babies, impact on identity, implications for society, deﬁni-
tions of genetic modiﬁcation and reproductive choice.
Growing points: The UK government legalized the techniques in March
2015. Scientiﬁc and medical communities across the world followed the
developments with interest.
Areas timely for developing research: It is expected that the ﬁrst cohort of
‘three parent’ babies will be born in the UK in 2016. Their health and
progress will be closely monitored.
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Introduction
In February 2015, UK Parliament voted in favour,
by a large majority, of changing the law to support
the clinical application of novel in vitro fertilization
(IVF) procedures involving mitochondrial donation.
The result is that the UK remains at the vanguard
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of mitochondrial science—it is currently the only
country in the world to legalize germ-line technologies.1
However, the techniques have attracted intense media
interest, with ‘three-parent babies’ dominating the head-
lines and concerns raised about the possible ‘slippery
slope’ to designer babies and human modiﬁcation. This
article explores the social and ethical issues surrounding
the legalization of these techniques.
Mitochondria exist in the cytoplasm of a cell and
are inherited through the female line. This means that
the children of women with disease caused by muta-
tions in mitochondrial DNA will inherit these muta-
tions. There is no cure for mitochondrial disease, and
treatment is limited,2 which means technologies that
can prevent a child from inheriting the disease have
been widely welcomed. Scientists at the Wellcome
Trust Centre for Mitochondrial Research in Newcas-
tle have developed two related techniques. Maternal
spindle transfer involves removing the nucleus of an
egg with faulty mitochondria from a woman with
mitochondrial disease and transferring it into a
donated e-nucleated egg containing healthy mito-
chondria. In contrast, pro-nuclear transfer occurs
after fertilization (see Fig. 1). In both cases, the mito-
chondrial DNA from the donor could be inherited by
future generations.
Fig. 1Maternal spindle transfer.
174 R. Dimond, 2015, Vol. 115








What is mitochondrial disease?
Mitochondria are small structures contained in the
cytoplasm of a cell, producing energy in the form of
adenosine triphosphate (ATP). Each cell contains
hundreds to thousands of mitochondria, depending
on the energy requirements of particular tissues.
Mitochondrial DNA is made up of 37 genes, which
are primarily responsible for maintaining the func-
tion of the mitochondria, making up <0.1% of our
body’s total DNA. Although the genetic contribution
of mitochondria is small, the impact when they fail
to function is considerable. Mitochondria dysfunc-
tion can be due to mutations in either nuclear or
mitochondrial DNA sequences. This article focuses
on diseases caused by mutations in mitochondrial
DNA sequences. As mitochondria are derived
through the oocyte (only one case of paternal inherit-
ance of mitochondria DNA has been identiﬁed3)
disease caused by mutations of mitochondrial DNA
display a maternal inheritance pattern. Both sexes
can inherit the disease but it is only women who are
at risk of transmitting the disease to their children.
Although it is difﬁcult to identify disease preva-
lence,4 it is estimated that one in 400 people carries a
disease causing mitochondrial mutation.5 Mitochon-
drial disease is extremely variable according to which
organs are affected and to what extent, and patients
can be mildly, severely or fatally affected. Symptoms
can include diabetes, epilepsy, digestive disorders,
fatigue, cardiomyopathy, deafness, restricted sight and
difﬁculties with mobility and balance. The term ‘mito-
chondrial disease’ was introduced in the late 1980s,
but it encompasses a range of distinct disorders,
including mitochondrial encephalomyopathy, lactic
acidosis and stroke like episodes (MELAS), myoclonus
epilepsy with RRF (MERRF), Leber’s hereditary optic
atrophy (LHON) and Leigh syndrome. The distinc-
tions between these classiﬁcations and their implica-
tions for clinical management are beyond the scope of
this paper and are described elsewhere.6–8
Why the controversy?
Mitochondrial donation is a germ-line technology
and a change in law was required for it to be used in
clinical practice. The techniques, and the scientists
involved, have attracted both widespread support
and consternation. The work at Newcastle is partly
funded by Muscular Dystrophy UK and, based on
the submissions to the public appeal for evidence,9
there is widespread support from patients with mito-
chondrial disease and their families. Indeed the need
to listen to and support the wishes of parents and
patients was noted in a letter from scientists, includ-
ing ﬁve Nobel Prize winners.10 It also highlighted the
importance of acting quickly, where parents ‘should
not have to wait for the law to catch up’, now that
the technology is available. Another letter written by
40 scientists from 14 different countries11 explained
why they supported the techniques:
A positive vote would not only allow affected
families to choose to use this new procedure
under the care of the globally respected Newcas-
tle team, with proper advice and safeguards; it
would also be an international demonstration of
how good regulation helps medical science to
advance in step with wider society.
The legalization of mitochondrial disease has
national and international signiﬁcance. The process
has been open to intense enquiry and mitochondrial
donation is one of the most scrutinized techniques in
recent history. Three scientiﬁc reviews by an expert
panel,12 a dialogue exercise to assess public attitudes
delivered by Sciencewise,13 a call for evidence on the
ethical issues organized by the Nufﬁeld Council on
Bioethics,14 a public consultation and government
guidance on draft regulations led by the UK Depart-
ment of Health9,15 and several debates within the
Houses of Parliament16,17 have been conducted. This
article will explore six issues raised by mitochondrial
donation and its debates. These are: concerns about
safety; the creation of three-parent babies; the impact
on a child’s identity; the implications for society; deﬁni-
tions of genetic modiﬁcation and reproductive choice.
Are the techniques safe?
The question of safety, of course, is a key issue for
any new medical technologies, particularly those
that involve reproduction. The techniques have been
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shown to be successful in mice18 and monkeys19 but
animal models do not necessarily translate to human
subjects.20 The Human Fertilisation and Embry-
ology Authority (HFEA) regulates the use of gametes
and embryos in assisted reproduction and research
within the UK. At the request of the Department of
Health, the HFEA conducted three scientiﬁc reviews.
A panel of experts reported on, and assessed evi-
dence about the safety and efﬁcacy of mitochondrial
replacement techniques. Questions were raised in
particular about the role of mitochondrial DNA and
the interactions between mitochondrial DNA and
nuclear DNA. Two further concerns were raised.
The ﬁrst was whether the embryo was at risk if there
was a mismatch between the mtDNA haplotype of
the mitochondria donor and that of the intending
mother.21,22 Although these concerns were later dis-
missed by the Chair of the HFEA’s expert panel,23
the report acknowledged that there was a lack of
research evidence and that licenced clinics could con-
sider haplotype matching as a precaution. The second
issue raised was the question of whether some of the
faulty mitochondria would remain attached to the
nucleus during the process of transfer. The panel con-
cluded that although it is possible that mitochondria
‘carry over’ can occur, this would be such a small per-
centage that it would be unlikely to be problematic. It
also noted that research had progressed during the
last few years but further experiments were critical.
Subsequently, it was made clear that these experi-
ments did not need to be carried out before legisla-
tion.24 The report12 concluded that the techniques
were potentially useful for a speciﬁc group of people,
that is, for women who want to have a genetically
related child and who are at risk of having a child
with severe mitochondrial disease.
Signiﬁcantly, the report found that the techniques
were ‘not unsafe’. This highlights the difﬁculties in
legislating for cutting edge, yet unproven, reproduct-
ive techniques. However, there is a history of related
techniques that could be used as evidence. In the
USA a procedure involving cytoplasm injection for
fertility treatment in older women resulted in the
birth of 17 children in 2000.25 Due to safety con-
cerns the Food and Drug Administration (FDA) sub-
sequently withdrew its licence, and it is reported that
subsequent attempts in China did not result in any
live births.26 It is only now, 15 years later, that a
project is underway to monitor the health of the sur-
viving children.27 The Department of Health has
recommended that any child born through the new
techniques of mitochondrial donation be involved in
clinical studies to monitor their current and future
health. Whether it is ethically acceptable to test chil-
dren,28 whether follow-up will extend to future gen-
erations and whether incentives will be needed to
encourage long-term participation are of course yet
to be decided.
Three-parent babies
Relationships produced through donation, and the
meanings we give them, are dependent on the legal,
social and cultural context. We expect very different
relationships between donor and recipient when the
donation is blood, for example, to when it involves a
living donation from a relative, or when it involves egg
or sperm donation. Mitochondrial donation involves
the transfer of genetic but not nuclear material, and
this has led to uncertainty as to whether it should be
regulated as egg donation or as tissue donation. Mito-
chondria play an important role in many bodily pro-
cesses, and therefore the genetic contribution of the
donor might be signiﬁcant: there are complex inter-
actions between nuclear DNA and mitochondrial
DNA21 and organelles contained in the cytoplasm
might introduce epigenetic alterations in nuclear
DNA.29 Headlines of ‘three-parent babies’ dominated
the debate, as they did more than 10 years ago when
the techniques ﬁrst started to be developed in the
UK.30 Although there is a difference between a genetic
parent and a social parent, focusing on biology alone
suggests that all babies born through these techniques
would be tri-parental.31 The Department of Health9
took a different view. Based on the extent of the
genetic contribution and the function of the genes
involved, it did not accept that the child born through
mitochondrial donation would have three parents:
Genetically, the child will, indeed, have DNA
from three individuals but all available scientiﬁc
evidence indicates that the genes contributing to
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personal characteristics and traits come solely
from the nuclear DNA, which will only come
from the proposed child’s mother and father. The
donated mitochondrial DNAwill not affect those
characteristics. (DoH, 2014 p 15)
Following the change in law32 the debate has to
some extent been settled. The relationship between
child and donor is now deﬁned as one where there is
no legal obligation towards each other. Whether or
not the child feels a genetic kinship with the mito-
chondria donor, knowing something about the donor
might still be important, for example, in providing a
fuller picture about the context of their conception.14
The legislation provides for this possibility, recom-
mending the child has access to non-identifying infor-
mation such as screening tests, family health and
personal information provided by the donor.
Implications for identity
Alongside questions of parentage, the concept of iden-
tity has remained central within the debate. Once
again, perspectives primarily differ according to the
perceived signiﬁcance of mitochondrial DNA. For
example, if our character and physical appearance is
considered to be solely determined by our nuclear genes
then as the Department of Health suggested, altering
mitochondrial genes might not have a signiﬁcant
impact on the child. But many reject this kind of genetic
essentialism. Identity is difﬁcult to deﬁne, but it is more
than our character and physical traits.33 Reproductive
medicine further complicates questions of identity.
Being born without mitochondrial disease would,
of course, have a signiﬁcant impact on the child. As
Bredenoord et al.34 highlight, ‘a person without a
mtDNA disease will have a different life experience, a
different biography and perhaps also a different char-
acter’. Through embryo selection or modiﬁcation,
many widely accepted reproductive technologies have
the potential to alter an individuals’ identity. Mito-
chondrial donation is therefore not necessarily a
special case.14
Implications for society
Whereas the discussions about identity and donor–
child relationships focus primarily on the personal
impact of the techniques, concerns have also been
raised about the wider implications for society.
Writing in a letter to the Times, 55 Italian Members
of Parliament35 urged British MPs to vote against
legalisation, drawing attention to the pace of devel-
opment and the consequences for ‘the whole of
humanity’:
The creation of such embryos could have un-
controllable and unforeseeable consequences, affect-
ing future generations, and modifying genetic
heritage in an irreversible way, inevitably affecting
the human species as a whole. It is a dangerous
intervention involving genetic engineering, which
affects the whole of humanity, and cannot possibly
be contained within the conﬁnes of the UK.
Indeed, many of those who have spoken out against
mitochondrial donation do so on the basis of per-
sonal beliefs. There appeared confusion within the
church as to whether there were legitimate grounds
to oppose the techniques. The Church of England36
had initially advised caution given the current level
of knowledge, suggesting the need for further scien-
tiﬁc review. In the House of Lords debate however,
it was made clear that ‘despite some misleading
headlines’, the Church was not opposed to mito-
chondrial donation. Although there can be blanket
opposition to some aspects of assisted reproduction
and embryo research based on the sanctity of
human life, in the context of this discussion, one
technique is considered particularly problematic.
Maternal spindle transfer and pro-nuclear transfer
both involve mitochondrial donation, but the latter
involves creating and destroying an embryo in the
process. As Fiona Bruce, Conservative MP for Con-
gleton, highlighted in the House of Commons
debate:
Let me be straightforward: I do oppose these pro-
posals in principle. However, that should not
prevent my concerns regarding their safety from
being given a fair hearing. One of the two proce-
dures that we are being asked to sanction today
—pro-nuclear transfer—involves the deliberate
creation and destruction of at least two human
embryos, and in practice probably more, to
create a third embryo, which it is hoped will be
free of human mitochondrial disease. Are we
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happy to sacriﬁce two early human lives to make
a third life?
Here the techniques are represented as two distinct
processes, with one technique being considered
unjustiﬁable. In contrast, the HFEA’s reports into
the safety of the techniques concluded that as there
was not enough evidence of the efﬁcacy of the techni-
ques to suggest one was preferable to the other, both
were recommended. This clear tension in perspec-
tives and approaches highlights the complex tangle
of ethical, legal and safety issues raised by mitochon-
drial donation.
Is this genetic modiﬁcation?
Another area of controversy is the impact of the tech-
niques on the human genome. The Department of
Health9 identiﬁed that the techniques involved germ-
line modiﬁcation, ‘in that the result of mitochondrial
donation – the avoidance of the transmission of a
serious mitochondrial disease – will be passed down
to future generations’. It concluded that the techni-
ques did not involve genetic modiﬁcation:
There is no universally agreed deﬁnition of
‘genetic modiﬁcation’ in humans – people who
have organ transplants, blood donations or even
gene therapy are not generally regarded as being
‘genetically modiﬁed’. While there is no universally
agreed deﬁnition, the Government has decided to
adopt a working deﬁnition for the purpose of
taking forward these regulations. The working
deﬁnition that we have adopted is that genetic
modiﬁcation involves the germ- line modiﬁcation
of nuclear DNA (in the chromosomes) that can be
passed on to future generations. This will be kept
under review.
The UK government has strongly defended its deci-
sion to use the ‘working deﬁnition’ of genetic modiﬁ-
cation which excludes mitochondrial DNA. The
techniques are viewed as replacing faulty mitochon-
drial genes, while leaving both the nuclear DNA and
mitochondrial DNA intact.16 Leading scientists have
questioned this position, accusing the government
of dishonesty, misleading the public and acting by
stealth.37
In anticipation of these concerns, the government
and leading supporters have attempted to clearly
demarcate the boundaries between mitochondrial
donation and nuclear modiﬁcation. Making clear
that this is not genetic modiﬁcation is politically
prudent as it would have been unlikely that the
public would accept attempts to approve the modiﬁ-
cation of the nuclear genome at this stage. Addition-
ally, the legislation speciﬁes who are eligible to use
the techniques (women at risk of transmitting mito-
chondrial disease to their offspring). This would
mean that those wishing to use the techniques to
enhance fertility38 and lesbian couples who wish to
use the techniques so that the child has a genetic con-
tribution from both (one would be mitochondria
donor) would not be permitted.
Genetic risk and reproductive choice
Medical innovations are often imagined as a utopia.30
This is the case with mitochondrial donation, which is
represented as both a treatment and cure, potentially
eliminating severe forms of mitochondrial disease8
and affecting the lives of thousands of women.39,40
The suggestion of technological determinism that if
these techniques are available then this will ‘halt’ or
‘eradicate’ the disease is in contrast to the practical
difﬁculties associated with mitochondrial disease.
A complex relationship between genotype and pheno-
type, different mutation ratios in different organs, a
wide range of symptoms and levels of severity present
considerable difﬁculties for providing patients with
genetic counselling about risk and severity.41–43 It is
also in contrast with what we know about how indivi-
duals and families make sense of genetic risk in the
context of living with disease.44,45
Importantly, severity of disease in offspring
cannot be predicted on the basis of the severity of the
disease of the mother. One reason put forward for
this is the ‘bottleneck theory’.8,44 Put simply, replica-
tion of mitochondrial DNA between cells and redis-
tribution during oocyte maturation can lead to
extreme differences in levels of mutation. This means
that an asymptomatic mother can have a very
severely or fatally affected child. Indeed many of the
parents whose stories have been the focus of the
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mitochondrial debate46–48 did not know that they
were at risk of having a child with mitochondrial
disease, until their child was diagnosed.
Where the risks are known, how individuals
make sense of uncertainty and complexity of mito-
chondrial disease, how they assess the risk of having
a child with mitochondrial disease and how they
negotiate IVF technologies are important questions.
This has been explored in multiple contexts accord-
ing to different kinds of genetic disease and disease
transmission.49–51 In contrast, there has been little
reﬂection about the contexts within which reproduct-
ive decisions might be made by those with mitochon-
drial disease. There are alternatives to mitochondrial
donation. However, oocyte donation does not offer
the opportunity to have a genetically related child and
relies on a supply of donor eggs,52 and prenatal diag-
nosis and pre-implantation genetic diagnosis would
have limited success for those with homoplasmic mito-
chondrial disease.53 The Rare Mitochondrial Disease
Service for Adults and Children, which has centres in
Oxford, London and Newcastle, can provide genetic
counselling for women at risk of carrying a mitochon-
dria mutation and to assist with reproductive choices.
Widespread support for these techniques was
evident in the large number of women who came
forward to donate their eggs for this research following
a public appeal by Newcastle University. However,
here again there is controversy. Donating eggs is a
complex process,54 with potential risks for the healthy
donor, including ovarian hyperstimulation syndrome.
Although the proposed compensation payment for
egg donors of £500 is within current UK guidelines,
the payment has raised concerns about exploit-
ation.55 The progress of the techniques will rely on a
supply of donated eggs, yet the egg donors and their
health and safety have primarily been missing from
the debate.56
Conclusion
Mitochondrial medicine represents a rapidly changing
ﬁeld with newly emerging tools for diagnosis and risk
assessment. Maternal spindle donation and pro-nuclear
donation were legalized in March 2015, as techniques
that could allow women with mitochondrial disease the
opportunity to have healthy, genetically related chil-
dren. The process of legalization was not smooth nor a
foregone conclusion. The wide reaching safety reviews,
public dialogues, parliamentary debates and numerous
calls for evidence have highlighted the robust nature of
regulation in reproductive medicine in the UK. The
extensive interest shown by the media, scientists, reli-
gious and special interest groups, patients and the
general public demonstrate the strength of feeling in
support of, and against, the introduction of these tech-
niques and highlight the considerable challenges for
policy-makers. Within the debate it is difﬁcult to iden-
tify areas of agreement and many of the key elements
have attracted equally strong supporters and detractors.
The science is complicated, and there were disagree-
ments about the function of mitochondria, its interac-
tions with nuclear DNA and the health implications of
mitochondrial donation. There were also disagreements
about what deﬁnitions to use, what level of evidence is
appropriate, what risks are appropriate to take and
who should be protected.
Important conclusions have been drawn. The
HFEA, in assessing safety and efﬁcacy, concluded
that the techniques were ‘not unsafe’. The use of lan-
guage is interesting but for many was unsatisfactory.
The ultimate test for proving whether any novel IVF
techniques work is through human application, and
this involves accepting that there will be risks. The
Department of Health concluded that there was no
signiﬁcant genetic relationship between the child and
donor. These are important pronouncements which
will have a lasting impact on how society views the
technology, and on patients and their families.
The techniques and surrounding debates have
revealed considerable gaps between the capabilities
of health technologies and clinical application.
Mitochondrial donation has challenged our under-
standing of the symbolic importance of genetic mater-
ial. Attitudes often differed about the implications
of the genetic contribution. For those who believe
the genetic contribution is important and suggests
a genetic relationship between child and donor, mito-
chondrial donation appears similar to egg or sperm
donation. For those who minimise the genetic contri-
bution, mitochondrial donation is considered more
like tissue/organ donation, which leads to very
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different conclusions about the relationship between
the child and donor, and the potential to affect iden-
tity. Questions remain about how potential parents
will make sense of reproductive risk in the context of
complex and uncertain biomedical knowledge. Ques-
tions also remain about how individuals, families and
wider society will respond to these technological solu-
tions. As with many innovative medical technologies,
the movement of mitochondrial donation from bench
to bedside has and will continue to rely heavily on
pioneering female patients who are willing to accept
the risks.57 Being conceived through IVF or having
three parents (for example, through step-families or
adoption) is not unusual in our society. As Scully58
highlights, it is how society and families respond to
mitochondrial donation as a ‘new kind of normal’
that will be important.
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